TIDMKNB
Kanabo Group PLC
02 November 2023
2 November 2023
Kanabo Group Plc
("Kanabo", the "Group" or the "Company")
Partnership with BRITISH CANNABIS(TM)
Kanabo Group plc (LSE: KNB), the patient-focused provider of
digital health services and specialist medicines, including
medicinal cannabis, is pleased to announce that it has entered into
a partnership with BRITISH CANNABIS(TM) to supply the CBD by
BRITISH CANNABIS(TM) range of pharmacy-grade CBD health supplements
to patients via a prescription service through the Group's online
pain management clinic, Treat It .
The partnership will allow doctors to prescribe the CBD by
BRITISH CANNABIS(TM) products to patients via the Treat It
platform. Focused on secondary care, Treat It enables patients
access to healthcare professionals via its secure, digital
healthcare platform. These medical professionals deliver a full
diagnosis as part of a personalised patient care plan and are able
to offer treatments, including the prescription of medicinal
cannabis, for individuals seeking relief from chronic pain. By
incorporating CBD by BRITISH CANNABIS(TM) products into our
offerings, Kanabo continues to increase the accessibility and
affordability of high quality, alternative pain management
solutions to improve overall patient quality of life.
From November, Treat It will also be included in Canndr, an
online medicinal cannabis app from BRITISH CANNABIS(TM) which
enables patients to select and review quality cannabis medicines on
the market, gain consultancy advice and select from a number of
suitable prescribing clinics.
Avihu Tamir, Chief Executive Officer of Kanabo, commented:
"At Kanabo, we aim to increase medicinal cannabis access for
more patients. This partnership allows Treat It doctors to include
a wider range of quality CBD supplements in our telemedicine
offerings. We're eager to further enhance patient-centric
healthcare and treatment options. This partnership is just the
beginning, and we hope to announce more expansive collaborations in
due course."
Steve Batchelor, BRITISH CANNABIS(TM) Marketing Director
commented:
"We are thrilled to join forces with Treat It to make CBD
products from our long-standing pharmacy retail brand accessible to
pain patients through prescriptions. This partnership represents a
significant step forward in expanding patient choices and
empowering doctors to explore naturally-derived supplements, as
alternatives to traditional pharmaceutical care paths.
"We are also pleased that thousands of long-term CBD customers
will have the option to consult with Treat It's network of
specialist pain doctors, assessing their own particular needs and
determining things like what delivery formats, when and how much
CBD they could be taking."
Enquiries:
Kanabo Group plc via Vigo Consulting
Avihu Tamir, Chief Executive Officer +44 (0)20 7390 0230
Assaf Vardimon, Chief Financial Officer
Ian Mattioli, Non-Executive Chair of the Board
Peterhouse Capital Ltd (Financial Adviser)
Eran Zucker / Lucy Williams / Charles Goodfellow +44 (0)20 7469 0930
Vigo Consulting (Financial Public Relations/Investor
Relations)
Jeremy Garcia / Fiona Hetherington / Verity
Snow +44 (0)20 7390
kanabo@vigoconsulting.com 0230
About BRITISH CANNABIS(TM)
BRITISH CANNABIS(TM) are pioneers in the UK cannabis industry
since 2015, specialising in high-quality CBD products trusted by
pharmacists and over 40,000 consumers alike. With over six years of
experience and a strong reputation, BRITISH CANNABIS(TM) is
dedicated to providing natural wellness solutions and promoting
education surrounding CBD.
About Kanabo Group plc
Kanabo Group plc (LSE:KNB) is a digital health company committed
to transforming patient care through its innovative technology
platform and specialised treatment offerings. Since its inception
in 2017, Kanabo has been focused on researching, developing, and
commercialising regulated medicinal cannabis-derived formulations
and therapeutic inhalation devices.
Kanabo's NHS-approved online telehealth platform, The GP
Service, provides patients with video consultations, online
prescriptions, and primary care services. Leveraging its telehealth
capabilities, in February 2023, Kanabo launched Treat It - an
online clinic focused on chronic pain management providing patients
with secondary care.
With its two complementary business divisions, Kanabo has
established itself as an end-to-end digital health provider,
offering telehealth consultations, prescriptions, alongside the
delivery of tailored treatments.
The Company's partially owned subsidiary, Kanabo Agritec Ltd, is
a cultivation consultancy supporting cannabis businesses in
developing new farms through infrastructural, research, and product
guidance. These farms deliver high-quality raw materials for
Kanabo's formulas and product line.
At Kanabo Group Plc, we are dedicated to providing patients with
the highest quality medical treatments and more accessible
healthcare experiences.
Visit www.kanabogroup.com for more information.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABBBMTMTTMTRJ
(END) Dow Jones Newswires
November 02, 2023 03:00 ET (07:00 GMT)
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
